Publications by authors named "Stan Bukofzer"

Claim this Profile
P
Partial vasopressin 1a receptor agonism reduces portal hypertension and hyperaldosteronism and induces a powerful diuretic and natriuretic effect in rats with cirrhosis and ascites.
Guillermo Fernández-Varo, Wladimiro Jiménez, Edward Cable, Pere Ginès, Geoff Harris, Stan Bukofzer

Biomed Pharmacother· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers.
Yu Bagger, William R Ravis, Geoff Harris, Stan Bukofzer

Clin Drug Investig· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OCE-205 in rats and non-human primates: Pharmacokinetic and pharmacodynamic analysis.
Stan Bukofzer, Geoff Harris, Edward E Cable

Curr Res Pharmacol Drug Discov· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OCE-205, a Selective V1a Partial Agonist, Reduces Portal Pressure in Rat Models of Portal Hypertension.
Stan Bukofzer, Geoffrey Harris, Susan Song, Edward E Cable

J Exp Pharmacol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes.
Rifaat Safadi, Robert S Rahimi, Dominique Thabut, Jasmohan S Bajaj, Kalyan Ram Bhamidimarri, Stan Bukofzer

Clin Transl Sci· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Robert S Rahimi, Rifaat Safadi, Dominique Thabut, Kalyan Ram Bhamidimarri, Nikolaos Pyrsopoulos, Stan Bukofzer

Clin Gastroenterol Hepatol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industry perspective on the medical risk of visible particles in injectable drug products.
Stan Bukofzer, John Ayres, Anna Chavez, Minerva Devera, Jahanvi Miller

PDA J Pharm Sci Technol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.
R Todd Stravitz, Michelle Gottfried, Valerie Durkalski, Robert J Fontana, A James Hanje, Stan Bukofzer

Hepatology· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study.
Furqan H Tejani, Randall C Thompson, Rita Kristy, Stan Bukofzer

Int J Cardiovasc Imaging· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finding unrecognized information in overactive bladder clinical trial data: a new approach to understanding placebo and treatment effects.
Norman R Zinner, Larry P Ammann, Gabriel P Haas, Stephen W Janning, Weizhong He, Stan Bukofzer

Neurourol Urodyn· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.
Bruce M Prenner, Stan Bukofzer, Sarah Behm, Kathleen Feaheny, Bruce E McNutt

J Nucl Cardiol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.
Karthik Ananthasubramaniam, Robert Weiss, Bruce McNutt, Barbara Klauke, Kathleen Feaheny, Stan Bukofzer

J Nucl Cardiol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis